Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifapentine

FDA-approved product (tablet, oral), marketed as Priftin, Rifapentine.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Rifapentine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
FDA pharmacologic class
Rifamycin Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB05; FDA class Rifamycin Antimycobacterial

Repurposing investigation

Rifapentine is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA98.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
  • E. coli76.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis95.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rifapentine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifapentine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)

    NCT07595042 · start 2026-10-30

    Registered record
    Registry ID
    NCT07595042
    Conditions
    Tuberculosis
    Interventions
    Isoniazid; Rifampin; Pyrazinamide; Ethambutol; Rifapentine; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-30
    Completion
    2029-10-22
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionIsoniazid; Rifampin; Pyrazinamide; Ethambutol +2 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV

    NCT07124559 · start 2026-10-15

    Registered record
    Registry ID
    NCT07124559
    Conditions
    Tuberculosis
    Interventions
    Rifapentine; Isoniazid; Dolutegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-15
    Completion
    2028-05-31
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine; Isoniazid; Dolutegravir
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Rifapentine-Based Shorter Regimens for Tuberculosis and TB Infection in Kazakhstan

    NCT07668479 · start 2026-07-01

    Registered record
    Registry ID
    NCT07668479
    Conditions
    Tuberculosis; Tuberculosis Infection, Latent; Tuberculosis, Pulmonary, Drug Sensitive
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-07-01
    Completion
    2027-08
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Tuberculosis Infection, Latent; Tuberculosis, Pulmonary, Drug Sensitive
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB

    NCT06568484 · start 2026-05-08

    Registered record
    Registry ID
    NCT06568484
    Conditions
    Tuberculosis, Latent
    Interventions
    Bedaquiline; Isoniazid, rifapentine; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2026-05-08
    Completion
    2027-09
    Enrolment
    2,530

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Latent
    InterventionBedaquiline; Isoniazid, rifapentine; Levofloxacin
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Window Prophylaxis for Pediatric Tuberculosis Prevention Trial

    NCT07086820 · start 2025-10-27

    Registered record
    Registry ID
    NCT07086820
    Conditions
    Tuberculosis Infection; Household Contacts; Children; Adolescent; Tuberculosis Infection, Latent; Tuberculosis
    Interventions
    Tuberculosis window prophylaxis with weekly rifapentine and isoniazid for 12 weeks; Standard of care tuberculosis prophylaxis with weekly rifapentine and isoniazid for 12 weeks
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-10-27
    Completion
    2028-11
    Enrolment
    647

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis Infection; Household Contacts; Children; Adolescent +2 more
    InterventionTuberculosis window prophylaxis with weekly rifapentine and isoniazid for 12 weeks; Standard of care tuberculosis prophylaxis with weekly rifapentine and isoniazid for 12 weeks
    PhaseNot applicable
    Registry statusRecruiting

  • Shorter and Safer Treatment Regimens for Latent TB

    NCT06498414 · start 2025-06-10

    Registered record
    Registry ID
    NCT06498414
    Conditions
    Tuberculosis Infection, Latent
    Interventions
    rifampin standard arm; rifampin double dose; levofloxacin and rifapentine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2025-06-10
    Completion
    2029-06-01
    Enrolment
    1,800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis Infection, Latent
    Interventionrifampin standard arm; rifampin double dose; levofloxacin and rifapentine
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis

    NCT06917495 · start 2025-04-05

    Registered record
    Registry ID
    NCT06917495
    Conditions
    Mild Spinal Tuberculosis
    Interventions
    Rifampin; Isoniazid; Rifapentine (RPT); Moxifloxacin; Pyrazinamide; Ethambutol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-04-05
    Completion
    2029-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild Spinal Tuberculosis
    InterventionRifampin; Isoniazid; Rifapentine (RPT); Moxifloxacin +2 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Shortened Regimen for Drug-susceptible TB in Children

    NCT06253715 · start 2025-01-15

    Registered record
    Registry ID
    NCT06253715
    Conditions
    Tuberculosis; Tuberculosis, Pulmonary; Tuberculosis, Lymph Node; Mycobacterium Tuberculosis
    Interventions
    Isoniazid; Rifampin; Pyrazinamide; Ethambutol; Rifapentine; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-01-15
    Completion
    2027-09-30
    Enrolment
    860

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Tuberculosis, Pulmonary; Tuberculosis, Lymph Node; Mycobacterium Tuberculosis
    InterventionIsoniazid; Rifampin; Pyrazinamide; Ethambutol +2 more
    PhasePhase 3
    Registry statusRecruiting

  • Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention

    NCT06281834 · start 2024-11-15

    Registered record
    Registry ID
    NCT06281834
    Conditions
    Pediatric HIV Infection; Latent Tuberculosis
    Interventions
    Rifapentine; Dolutegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-11-15
    Completion
    2027-06-01
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric HIV Infection; Latent Tuberculosis
    InterventionRifapentine; Dolutegravir
    PhasePhase 1
    Registry statusRecruiting

  • Introduction of Dispersible 3HP Formulations for TB Preventive Treatment in Children: a Multi-country Evaluation

    NCT06511180 · start 2024-08

    Registered record
    Registry ID
    NCT06511180
    Conditions
    TB - Tuberculosis; Household Contact; HIV; Children, Only
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-08
    Completion
    2025-06
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTB - Tuberculosis; Household Contact; HIV; Children, Only
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • BCG Revaccination in Children and Adolescents

    NCT05330884 · start 2024-07-15

    Registered record
    Registry ID
    NCT05330884
    Conditions
    Tuberculosis Infection; Tuberculosis
    Interventions
    BCG vaccine; Oral Chemoprophylaxis
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Suspended
    Start
    2024-07-15
    Completion
    2027-12
    Enrolment
    9,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis Infection; Tuberculosis
    InterventionBCG vaccine; Oral Chemoprophylaxis
    PhasePhase 3
    Registry statusSuspended

  • Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease

    NCT05021731 · start 2024-04-20

    Registered record
    Registry ID
    NCT05021731
    Conditions
    Latent Tuberculosis; Kidney Failure
    Interventions
    Rifampicin plus Isoniazid; Rifapentine plus Isoniazid; Rifampicin alone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-04-20
    Completion
    2025-04-30
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis; Kidney Failure
    InterventionRifampicin plus Isoniazid; Rifapentine plus Isoniazid; Rifampicin alone
    PhasePhase 4
    Registry statusUnknown

  • ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa

    NCT06214910 · start 2024-02-20

    Registered record
    Registry ID
    NCT06214910
    Conditions
    Tuberculosis; HIV I Infection
    Interventions
    Community-delivered TB preventive therapy (TPT) - 3 months weekly isoniazid plus rifapentine (3HP); Clinic-link TPT
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-02-20
    Completion
    2025-08-04
    Enrolment
    301

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; HIV I Infection
    InterventionCommunity-delivered TB preventive therapy (TPT) - 3 months weekly isoniazid plus rifapentine (3HP); Clinic-link TPT
    PhaseNot applicable
    Registry statusCompleted

  • Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis

    NCT05630872 · start 2024-02-13

    Registered record
    Registry ID
    NCT05630872
    Conditions
    HIV-associated Tuberculosis
    Interventions
    Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC; DTG 50 mg orally QD plus TDF/3TC; 2HPZM; 2HPM
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-02-13
    Completion
    2025-11-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-associated Tuberculosis
    InterventionDolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC; DTG 50 mg orally QD plus TDF/3TC; 2HPZM; 2HPM
    PhasePhase 2
    Registry statusCompleted

  • Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV

    NCT05122026 · start 2024-01-17

    Registered record
    Registry ID
    NCT05122026
    Conditions
    HIV Seropositivity; Pregnancy; Tuberculosis Infection
    Interventions
    Rifapentine; Isoniazid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2024-01-17
    Completion
    2025-12-31
    Enrolment
    252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Seropositivity; Pregnancy; Tuberculosis Infection
    InterventionRifapentine; Isoniazid
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting